Skip to main content
OpenTrials
Completed

NCT Number: NCT05576155

Sex Differences in the Dilatory Response of Compound 21

When blood pressure changes, Angiotensin II is produced and released into the bloodstream. This substance can make blood vessels smaller (i.e., vasoconstriction) by acting through Angiotensin II type I receptors (AT1R) to increase blood pressure. Or it can increase the diameter of vessels (i.e., vasodilation) through Angiotensin II type II receptors (AT2R) to decrease blood pressure. These two receptors normally work in balance to maintain blood pressure. However, excess Angiotensin II released in the bloodstream may reduce the sensitivity of AT2Rs, leading to excessive activation of AT1Rs. This results in increased constriction which plays a major role in diseases such as high blood pressure, hardening of the arteries, and heart failure. In the body, Angiotensin II production is reduced in the presence of estrogen, as seen in pre-menopausal women. Pre-menopausal women have a greater protection against cardiovascular diseases compared to age-matched males, likely due to the protective effects of estrogen. However, the extent that estrogen may impact the sensitivity of Angiotensin II receptors in pre-menopausal is unknown.

In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents), the blood vessels in a dime-sized area of the skin are studied in healthy young women and men. As a compliment to these measurements, blood is drawn from the subjects and circulating factors that may contribute to cardiovascular health are measured.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

University of Iowa

Iowa City, Iowa, 52242, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Young women or men,
  • 18-35 years old,
  • Body mass index between 18 and 30 kg/m2,
  • Systolic blood pressure <140,
  • Diastolic blood pressure <90 mmHg.

Exclusion criteria

  • Skin allergies, skin disorders, or skin diseases such as Raynaud's phenomenon or other history of cold intolerance,
  • History of metabolic or cardiovascular disease,
  • Taking medications that could alter vascular function, including antidepressants, anxiety medications, or cholesterol or blood pressure lowering drugs,
  • Women with oligo- or amenorrhea,
  • Women that are pregnant or nursing
  • current tobacco use,
  • Allergy to materials used during the experiment (e.g. latex).

Treatment and study plan

Compound 21

Drug

Compound 21 + Ringer's is perfused at 10 doses increasing serially for 10 minutes each from 10^-12 M to 10^-3 M

Compound 21 + losartan

Drug

Compound 21 + losartan (43 µM) is perfused at 10 doses increasing serially for 10 minutes each from 10^-12 M to 10^-3 M.

Primary outcomes

  1. Microvascular AT2R Sensitivity Following Local Control Treatment

    Time frame: post 1 hour of local control treatment

    cutaneous vascular vasodilator response to exogenous Compound 21 perfusion; measured with laser-Doppler flowmetry coupled with intradermal microdialysis delivery of Compound 21 in young men and women

  2. Microvascular AT2R Sensitivity Following Local AT1R Inhibition

    Time frame: post 1 hour of local losartan treatment

    cutaneous vascular vasodilator response to exogenous Compound 21 perfusion; measured with laser-Doppler flowmetry coupled with intradermal microdialysis delivery of Compound 21 co-infused with losartan young men and women

Secondary outcomes

  1. Circulating Progesterone and Testosterone

    Time frame: at the start of the experimental visit, immediately prior to local losartan treatment

    plasma measurement of circulating progesterone and testosterone; measured by ELISA in plasma samples

  2. Circulating Estradiol

    Time frame: at the start of the experimental visit, immediately prior to local losartan treatment

    plasma measurement of circulating estradiol, measured by ELISA in plasma samples

Sponsors and collaborators

Lead sponsor

Anna Stanhewicz, PhD

Other

Registry information

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Oct 12, 2022
Registry last updated
Dec 31, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.